Citius Pharmaceuticals (CTXR) - צמיחת רווחי EPS רבעונית
Citius Pharmaceuticals is expanding its presence in the intensive care and oncology segments by attracting the hospital sector. The Mino-Lok product enables the treatment of infections without removing catheters, thereby reducing clinic costs. Simultaneously, the company is implementing energy-efficient technologies and the safe disposal of chemicals. This chart on GURU.Markets reflects the growth rates of quarterly net income per share, where this metric stands at 57.40.
%20%D7%A6%D7%9E%D7%99%D7%97%D7%AA%20%D7%A8%D7%95%D7%95%D7%97%20%D7%A0%D7%A7%D7%99%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%9E%D7%A9%D7%A0%D7%94%20%D7%9C%D7%A9%D7%A0%D7%94%20%D7%91-12%20%D7%94%D7%97%D7%95%D7%93%D7%A9%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwejrfjc.e5f-7d7lczk&start=20220704&end=20261113&filename=GURU_Markets_-_CTXR_-_Citius-Pharmaceuticals_-_Year-over-year-net-earnings-per-share-growth-for-the-last-12-months "צמיחת רווח למניה משנה לשנה בשנים עשר החודשים האחרונים Citius Pharma (CTXR): לתקופה 04.07.2022 - 13.11.2026 | 👁️GURU.Markets👁️")
פילוחים אנליטיים של חברת Citius Pharmaceuticals
Citius Pharmaceuticals (CTXR) is investing in the development of biodegradable gels and protein synthesis for the therapy of critical conditions, which necessitates strict control over financial efficiency. The quarterly earnings per share (EPS) growth trend measures the rate of change in net income, allowing investors to determine via the current quarterly EPS growth level whether fundamental successes justify the market value or if the asset is overvalued.
